Pfizer recalls some batches of blood pressure drugs over a carcinogen
- New drug Zanubrutinib reduces tumor size in 80% of lymphoma patients
- Study shows robotic surgery is safer and reduces patient recovery time by 20%
- What is the relationship between Harmful metabolites of TME and antitumor immunity?
- What we should know and reflect on Monkeypox outbreak?
- Nucleic acid drugs can achieve functional cure of hepatitis B
- Scientists find effects of COVID-19 infection on thyroid can last at least a year
Pfizer recalls some batches of blood pressure drugs over a carcinogen
- How long can the patient live after heart stent surgery?
- More than 500 new drugs for blood diseases are in development
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Pfizer recalls some batches of blood pressure drugs over a carcinogen.
U.S. pharmaceutical giant Pfizer said on April 22 that it was recalling five batches of its blood pressure drug Accupril after it found elevated levels of a potential carcinogen in its blood pressure drug, Reuters just reported.
Pfizer said it has not identified any reports of adverse events related to the recalled batches. The drugs were sold in the U.S. and Puerto Rico from December 2019 to April 2022.
Pfizer Canada also recalled all batches of three doses of Accupril on Thursday after finding the same impurity above acceptable levels.
Pfizer said nitrosamines have been found in the drug, but there is no immediate risk to patients taking the drug.
Nitrosamines are common in water and food, but chronic intake of nitrosamines above acceptable levels increases the risk of cancer.
Pfizer last month also recalled some batches and two authorized cheaper versions of another blood pressure drug, Accuretic, because of a possible carcinogen in it.
News on March 27
On March 21, Pfizer voluntarily recalled 3 commonly used antihypertensive drugs because of a notice of voluntary recall of drugs.
Half a month ago, on March 4, Pfizer Canada recalled the same blood pressure lowering drug in the Canadian market. The reasons for the two recalls are also the same.
In the past five years, Pfizer has recalled a total of 14 times across the United States, involving 16 drugs, and has repeatedly been caught in the “recall door”. of global pharmaceutical companies continue to face doubts about the quality and safety of medicines.
(source:internet, reference only)
Disclaimer of medicaltrend.org
